CA3191410A1 - Sulphamoyl urea derivatives containing alkyl-oxacycloalkyl moiety and uses thereof - Google Patents
Sulphamoyl urea derivatives containing alkyl-oxacycloalkyl moiety and uses thereofInfo
- Publication number
- CA3191410A1 CA3191410A1 CA3191410A CA3191410A CA3191410A1 CA 3191410 A1 CA3191410 A1 CA 3191410A1 CA 3191410 A CA3191410 A CA 3191410A CA 3191410 A CA3191410 A CA 3191410A CA 3191410 A1 CA3191410 A1 CA 3191410A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- disease
- disorder
- present disclosure
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063074521P | 2020-09-04 | 2020-09-04 | |
| US63/074,521 | 2020-09-04 | ||
| PCT/US2021/049001 WO2022051582A1 (en) | 2020-09-04 | 2021-09-03 | Sulphamoyl urea derivatives containing alkyl-oxacycloalkyl moiety and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3191410A1 true CA3191410A1 (en) | 2022-03-10 |
Family
ID=77951864
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3191410A Pending CA3191410A1 (en) | 2020-09-04 | 2021-09-03 | Sulphamoyl urea derivatives containing alkyl-oxacycloalkyl moiety and uses thereof |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240043410A1 (enExample) |
| EP (1) | EP4208459A1 (enExample) |
| JP (1) | JP7865948B2 (enExample) |
| KR (1) | KR20230061505A (enExample) |
| CN (1) | CN116783184A (enExample) |
| AR (1) | AR123435A1 (enExample) |
| AU (1) | AU2021336518B2 (enExample) |
| BR (1) | BR112023003792A2 (enExample) |
| CA (1) | CA3191410A1 (enExample) |
| IL (1) | IL301055A (enExample) |
| MX (1) | MX2023002686A (enExample) |
| TW (1) | TWI916398B (enExample) |
| WO (1) | WO2022051582A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201721185D0 (en) | 2017-12-18 | 2018-01-31 | Nodthera Ltd | Sulphonyl urea derivatives |
| HUE067378T2 (hu) | 2019-06-12 | 2024-10-28 | Nodthera Ltd | Szulfonilurea származékok és alkalmazásaik |
| JP7661248B2 (ja) | 2019-06-12 | 2025-04-14 | ノッドセラ リミテッド | スルホニル尿素誘導体及びその使用 |
| KR20260115622A (ko) * | 2023-11-17 | 2026-07-24 | 노드테라 리미티드 | 우레아 유도체의 제조 방법 |
| CN122555701A (zh) | 2023-11-17 | 2026-08-11 | 诺瑟拉有限公司 | 脲衍生物的形式和相关用途 |
| TW202545527A (zh) * | 2024-01-16 | 2025-12-01 | 英商諾得瑟拉公司 | Ｎｌｒｐ３及ｇｌｐ－１ａ組合療法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
| DK1270565T3 (da) | 1997-01-29 | 2004-10-04 | Pfizer | 4-substitueret furan-2-sulfonamid og dets anvendelse i fremstillingen af sulfonylurinstofderivater |
| JP6929792B2 (ja) * | 2015-02-16 | 2021-09-01 | ザ ユニバーシティ オブ クィーンズランド | スルホニル尿素及び関連化合物並びにその使用 |
| JP7412328B2 (ja) | 2017-07-24 | 2024-01-12 | ノバルティス アーゲー | Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 |
| GB201721185D0 (en) * | 2017-12-18 | 2018-01-31 | Nodthera Ltd | Sulphonyl urea derivatives |
| SG11202101480XA (en) | 2018-08-15 | 2021-03-30 | Inflazome Ltd | Novel sulfonamideurea compounds |
-
2021
- 2021-09-03 JP JP2023514910A patent/JP7865948B2/ja active Active
- 2021-09-03 EP EP21778667.2A patent/EP4208459A1/en active Pending
- 2021-09-03 MX MX2023002686A patent/MX2023002686A/es unknown
- 2021-09-03 WO PCT/US2021/049001 patent/WO2022051582A1/en not_active Ceased
- 2021-09-03 CA CA3191410A patent/CA3191410A1/en active Pending
- 2021-09-03 CN CN202180074301.7A patent/CN116783184A/zh active Pending
- 2021-09-03 KR KR1020237011396A patent/KR20230061505A/ko active Pending
- 2021-09-03 AU AU2021336518A patent/AU2021336518B2/en active Active
- 2021-09-03 US US18/043,883 patent/US20240043410A1/en active Pending
- 2021-09-03 AR ARP210102472A patent/AR123435A1/es unknown
- 2021-09-03 IL IL301055A patent/IL301055A/en unknown
- 2021-09-03 TW TW110132880A patent/TWI916398B/zh active
- 2021-09-03 BR BR112023003792A patent/BR112023003792A2/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL301055A (en) | 2023-05-01 |
| TWI916398B (zh) | 2026-03-01 |
| BR112023003792A2 (pt) | 2023-03-28 |
| AU2021336518A1 (en) | 2023-03-23 |
| EP4208459A1 (en) | 2023-07-12 |
| AU2021336518B2 (en) | 2026-05-21 |
| MX2023002686A (es) | 2023-04-03 |
| AR123435A1 (es) | 2022-11-30 |
| JP2023540733A (ja) | 2023-09-26 |
| US20240043410A1 (en) | 2024-02-08 |
| KR20230061505A (ko) | 2023-05-08 |
| JP7865948B2 (ja) | 2026-05-26 |
| WO2022051582A1 (en) | 2022-03-10 |
| TW202229265A (zh) | 2022-08-01 |
| CN116783184A (zh) | 2023-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021336518B2 (en) | Sulphamoyl urea derivatives containing alkyl-oxacycloalkyl moiety and uses thereof | |
| US12247011B2 (en) | Selective inhibitors of NLRP3 inflammasome | |
| CA3084694A1 (en) | Sulphonyl urea derivatives as nlrp3 inflammasome modulators | |
| US12624023B2 (en) | Sulfonylurea derivatives and uses thereof | |
| CN114641466B (zh) | 磺酰脲衍生物及其用途 | |
| US20220267300A1 (en) | Sulfonamide derivatives and uses thereof | |
| SG11202107653RA (en) | Carbamate derivatives and uses thereof | |
| RU2858266C2 (ru) | Производные сульфамоилмочевины, содержащие алкилоксациклоалкильную группу, и их применения | |
| US20250206745A1 (en) | Pyrrolopyridazine derivatives and related uses | |
| US20250115558A1 (en) | Pyridazine derivatives and related uses | |
| HK40031620A (en) | Selective inhibitors of nlrp3 inflammasome | |
| HK40031620B (en) | Selective inhibitors of nlrp3 inflammasome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240830 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240830 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240830 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250731 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250731 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250731 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250805 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250829 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250829 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251118 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20251118 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251118 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251118 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251119 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260616 |